STAT3 and skin neoplasm: A 15 bp double-stranded decoy oligonucleotide that correspond to the STAT3 response element in the cFOS promoter competitively inhibits STAT3 DNA binding and suppresses the tumor growth of preclinical models of ovarian, breast, head-and-neck, lung, brain, and skin cancers as well as acute myeloid leukemia [84–87].